

- Complement
 classical reaction, 127
 intermediate complexes, properties, activities and control of, 129
- Complement activation
 activities and pharmacologically active products of, 125
 alternate pathways, 136
 factors involved, 142
 anaphylatoxin formation, 137
 cobra venom, 141
 guinea pig immunoglobulins, 140
 lipopolysaccharides, 139
 pathway, C1 by-pass, 142
 properdin system, 136
 zymosan, 137
- Complement components, peptide fragments, active, 150
- Corticosterone levels, 6-hydroxydopamine effects on, 268
- Diet, natural *versus* synthetic, 190
- Dopa decarboxylase, substrate and inhibitor selectivity, 335
- Dopamine- β -hydroxylase, substrate and inhibitor selectivity, 337
- Dopamine receptors, criteria for investigation of, 358
- Drug-metabolizing enzyme system, role of nutrition, 171
- Drugs, prostaglandin biosynthesis inhibited by, 33
- Easson-Stedman hypothesis, 356
- Enzyme(s)
 alterations by 6-hydroxydopamine, 223
 catecholamine synthesizing, substrate and inhibitor selectivity, 335
 metabolizing, substrate and inhibitor selectivity, 337
- Enzyme system, drug-metabolizing, role of nutrition in, 171
- Fatty acids, inhibition of prostaglandin biosynthesis, 37
- Fever
 antipyretics and, 305, 310
 brain monoamines and, 308
 hypothalamic neurons, behaviour during, 307
 prostaglandins and pyrogen action, 309
 pyrogens and, 305
- Flower, Roderick J., Drugs which inhibit prostaglandin biosynthesis, 33
- Food intake, 6-hydroxydopamine effects on, 260
- Hayes, Johnnie. *See* Campbell and Hayes, 171
- Heart, β -adrenoreceptor antagonists in study of cardiac arrhythmia, 368
- Hellon, R. F., Monoamines, pyrogens and cations: Their actions on central control of body temperature, 289
- 6-Hydroxydopa, biological effects, 268
- 6-Hydroxydopamine
 behavioral alterations produced by, 259
 cardiovascular effects, 244
 catecholamine-containing neurons, morphological alterations after treatment with, 226
 central injections, 253
 development of postsynaptic supersensitivity after treatment with, 210
 development of presynaptic supersensitivity after treatment with, 209
 differential sensitivity of catecholamine-containing neurons to, 211
 effects on
 adrenergic sites, 210
 audiogenic seizures, 264
 body temperature, 261
 catecholamine-containing neurons in the central nervous system, 213
 catecholamine uptake, 222
 central putative transmitters, 228
 corticosterone levels, 268
 food intake, 260
 irritability and aggression, 266
 locomotor activity, 263
 melanophores, 268
 monoamine content of central nervous system, 213
 morphine-treated mice, 264
 operant activity, 267
 peripheral autonomic structures, 230
 reproductive physiology, 265
 skin grafts, 267
 sleep, 265
 sympathetic neurons in end organs, 237
 water intake, 260
 enzyme alterations by, 223
 false neurotransmitter role and nondestructive effects of, 203
 intraneuronal sites associated with destructive lesioning of, 206
 loss of conduction properties of noradrenergic terminal endings after treatment with, 208
 maternal treatment with, 254
 molecular mechanisms of action of, 254
 neonatal effects, 254
 neuronal interactions with, temporal sequence of, 202
 organ susceptibility to, differences, 236
 peripheral injections
 central nervous system, 250
 sympathetic nervous system, 246
 pharmacological actions of, 199
 route of administration, 230
 selectivity of uptake into catecholamine-containing neurons, 203

- studies, on developing neurons, 246
- sympathomimetic effects of, 205
- Hypothalamic neurons, antipyretic action on preoptic and anterior, 311
- Hypothalamus
 - antipyretic entry to, 311
 - monoamines in, 292
- Indomethacin, inhibitory and other effects, 50
- Immunoglobulins (guinea pig), complement activation, 140
- Isomers
 - actions and interactions, 333
 - α -adrenoreceptor blockade and, 364
 - effects at postjunctional sites, 356
 - purity, impurity and racemization with use of, 332
- Jacobowitz, David M. *See* Kostrzewa and Jacobowitz, 199
- Kostrzewa, Richard M., and David M. Jacobowitz, Pharmacological actions of 6-hydroxydopamine, 199
- Linear system
 - behavior prediction, 23
 - definition, 3
 - distinction from non-linear systems, 6
 - usefulness of specific models for, 23
- Linearity
 - concept of
 - application in theoretical studies, 18
 - in analysis of pharmacokinetic data, 12
 - superposition and, in pharmacokinetics, 3
- Lipids, effect of deficiency on mixed function oxidase system, 173
- Lipotropes, effect of deficiency on mixed function oxidase system, 174
- Locomotor activity, 6-hydroxydopamine effects, 263
- Melanophores, 6-hydroxydopamine effects on, 268
- Metabolizing enzymes, substrate and inhibitor selectivity, 337
- Metaraminol isomers, false neurochemical transmitter, 346
- α -Methyldopamine isomers, false neurochemical transmitter, 346
- α -Methylnorepinephrine isomers, false neurochemical transmitter, 344
- Miller, D. D. *See* Patil *et al.*, 323
- Minerals, effect of deficiency on mixed function oxidase system, 186
- Mixed function oxidase system
 - carbohydrate in, 172
 - lipids in, 173
 - lipotropes in, 174
 - mineral deficiencies in, 186
 - protein in, 176
 - vitamins in, 181
- Molecular geometry, adrenergic drug activity and, 323
- Monoamine oxidase, substrate and inhibitor selectivity, 337
- Monoamines
 - action on central control of body temperature, 289
 - fever and, 308
 - 6-hydroxydopamine effect on content of, in central nervous system, 213
 - presence in hypothalamus and brain stem, 292
- Monoaminergic neurons, agents causing possible degeneration of, 275
- Muscle, smooth, angiotensin action on, 70, 107
- Neurochemical transmitters, false, 344
- Neuroeffector junction, stereoselective processes, 330
- Norepinephrine, neuronal uptake, stereoselectivity of, 340
- Nutrition
 - deficiencies
 - macronutrient, 172
 - micronutrient, 181
 - general status, 188
 - natural *versus* synthetic diets, 190
 - role, in drug-metabolizing enzyme system, 171
- Park, W. K. *See* Regoli *et al.*, 69
- Patil, P. N., D. D. Miller, and U. Trendelenberg, Molecular geometry and adrenergic activity, 323
- Peptide fragments, pharmacologically active, of complement components, 150
- Pharmacokinetic data, concept of linearity in analysis of, 12
- Pharmacokinetics
 - linearity and superposition in, 3
 - theory, 6
- Pharmacokinetic systems, non-linearity, 25
- Phenthanolamine-N-methyl transferase, substrate and inhibitor selectivity, 337
- Properdin system, complement activation alternate pathway, 136
- Prostaglandin biosynthesis
 - drugs which inhibit, 33
 - chemistry of, 35
 - inhibition by
 - anti-oxidants, 55
 - aspirin-like drugs and other pharmacological agents, 42
 - heavy metal ions, 55
 - nucleotides, 55
 - substrate analogues and other fatty acids, 37
- Prostaglandin catabolism, inhibition of, 60

- Prostaglandin dehydrogenase, inhibition of, 60
Prostaglandin synthetase, distribution of, 37
Prostaglandins
 antipyretics and, 311
 effect on pyrogen actions, 309
Protein, effect of deficiency on mixed function oxidase system, 176
Pyrogens
 action on central nervous system, effects of prostaglandins, 309
 central control of body temperature, 289
 composition of, 306
 fevers and, 305
 site of action, 306
- Regoli, D., W. K. Park and F. Rioux, Pharmacology of angiotensin, 69
Rioux, F. *See* Regoli *et al.*, 69
- Skin grafts, 6-hydroxydopamine effects on, 267
Sleep, 6-hydroxydopamine effects on, 265
Sympathetic ganglia, angiotensin effects on, 112
Sympathetic nerve terminals, angiotensin effects on, 113
Sympathetic nervous system, 6-hydroxydopamine effects, peripheral injections, 246
- Synthetase preparations, drug sensitivity, 48
- Temperature
 transmitter substances and their central effects on, 291
 evidence from various species, 292
Temperature regulation
 as a control system, 290
 cations, central actions of, 313
Thron, C. D., Linearity and superposition in pharmacokinetics, 3
Trendelenberg, U. *See* Patil *et al.*, 323
Tyrosine hydroxylase, substrate and inhibitor selectivity, 335
- Uptake, inhibition of, 348
- Venom, cobra, complement activation, 141
Vitamins, effect of deficiency of, on mixed function oxidase system, 181
Vogt, Walther, Activation, activities and pharmacologically active products of complement, 125
- Water intake, 6-hydroxydopamine effects, 260